16
Jul 2026
Study suggests lipid droplet accumulation is a conserved feature of senescent cells
A new research paper was published in Volume 18 of Aging on July 1, 2026, titled "Senescent cells accumulate lipid droplets."
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
16
Jul 2026
PET imaging reveals widespread brain receptor deficits in schizophrenia
A groundbreaking study using positron emission tomography (PET) imaging has found that patients with schizophrenia had significantly lower muscarinic acetylcholine M1 receptor availability (~13% to 19%) across multiple brain regions compared with healthy individuals.
16
Jul 2026
Computational framework identifies synergistic compound pairs in herbal medicines
Herbal medicines have long been used in disease treatment, often through formulas that combine multiple herbs to enhance therapeutic effects and reduce side effects.
16
Jul 2026
Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.